1. Introduction {#s0005}
===============

Peripheral skeletal muscle wasting and dysfunction are major complications of critical illness, both occurring early and progressing rapidly [@bb0005]. The resulting intensive care unit--acquired weakness (ICU-AW) is a major factor contributing to "post--intensive care syndrome" evident in survivors [@bb0010]. Although there are data to support the use of exercise therapy to address physical deconditioning within the ICU [@bb0015; @bb0020; @bb0025; @bb0030; @bb0035; @bb0040] and after transfer to the ward [@bb0045; @bb0050; @bb0055], the clinical benefit beyond hospital discharge is controversial, and therefore, the delivery of such a service has been inconsistent. In the UK, despite the high profile of this area and publication of guidelines from the National Institutes of Health and Care Excellence [@bb0060], we have recently shown that there is lack of available services for post--critical illness patients [@bb0065]. Indeed, a paucity of evidence, including randomized controlled trial (RCT) data [@bb0070], to underpin these guidelines was identified as a barrier to their implementation [@bb0065]. Specifically, 3 recent interventional trials demonstrated little or no clinical benefit [@bb0045; @bb0075; @bb0080]. Interestingly, however, while methodological variation in the delivery of the intervention across these studies could have contributed to these results, none of these trials stratified patients by presence of ICU-AW or peripheral muscle wasting as an inclusion criterion, and thus, the target population may have been less likely to benefit from the intervention. Diagnosis of ICU-AW, measured by manual muscle testing, has previously been shown to demonstrate a causal association with poor clinical outcome [@bb0085; @bb0090; @bb0095; @bb0100; @bb0105; @bb0110; @bb0115; @bb0120], and therefore, these patients may have greater ongoing rehabilitation requirements.

This pilot trial investigated (1) the feasibility of an exercise-based rehabilitation program (EBRP) delivered after hospital discharge in patients with ICU-AW and (2) the clinical use of ICU-AW diagnosis as an eligibility criterion for enrolment. In addition, a nested observational study of patients without a diagnosis of ICU-AW was incorporated to define the trajectory of recovery of such patients.

2. Materials and methods {#s0010}
========================

2.1. Ethical approval {#s0050}
---------------------

Ethical approval was obtained from London Westminster Research Ethics Committee (London, UK, 09/H0802/80), and local Research & Development site-specific approval from participating organizations. Written informed consent was obtained from all participants.

2.2. Study design {#s0055}
-----------------

A pilot feasibility RCT of exercise rehabilitation was conducted in survivors of critical illness with ICU-AW with a nested parallel observational cohort study of post--critical illness patients without ICU-AW. Because of the pilot, feasibility nature of the study, there was no a priori calculated sample size.

2.3. Patients {#s0060}
-------------

Patients were recruited from the ICUs of 2 London teaching hospitals within an Academic Health Sciences Centre (60 beds in total). One hospital is a regional trauma and neurosciences center, and the other a tertiary referral center for advanced ventilation, with both having a general medical and surgical case mix.

2.4. Screening {#s0065}
--------------

All patients receiving mechanical ventilation (MV) during their ICU admission were screened for potential eligibility. Screening occurred over 6 sessions per week depending on availability of the research team. Participants were approached for recruitment at ICU discharge, and consenting patients were randomized into either standard care or intervention groups if they had evidence of ICU-AW as per definition [@bb0090]. If ICU-AW was not present, patients were enrolled into the observational study within 24 hours of ICU discharge.

2.5. Inclusion criteria {#s0070}
-----------------------

Inclusion criteria for enrolment included age 18 years or more, MV for 48 hours or more, Glasgow Coma Scale 15/15, survival to hospital discharge, and sufficient mobility to participate in an EBRP after hospital discharge. Specifically for inclusion into the RCT, participants were required a diagnosis of ICU-AW at ICU discharge. Participants in the observational cohort study did not demonstrate ICU-AW.

2.6. Exclusion criteria {#s0075}
-----------------------

Patients were excluded if they were palliative, had unstable cardiac disease, had limb amputation, neurological diagnoses, had peripheral vascular disease awaiting revascularization, had any musculoskeletal condition or extensive medical comorbidity precluding ability to exercise, had psychiatric illness, had requirement for ongoing renal dialysis, were an extracontractual referral and could not return to the hospital site, or had an existing rehabilitation pathway in place.

2.7. Assessment of ICU-AW {#s0080}
-------------------------

Assessment of ICU-AW was conducted as described previously [@bb0085; @bb0090; @bb0100] by the lead researcher. Adequate conscious level of patients was determined as a score of − 1 (drowsy) to + 1 (restless) on the Richmond Agitation Sedation Scale [@bb0125]. Awake patients were then required to demonstrate positive response to a battery of simple one-stage commands including "Open and close eyes" and "Stick out your tongue." Successful completion of these commands was followed by muscle strength assessment using the Medical Research Council Sum score (MRC-SS), a 6-point grading scale ranging from 0 (no visible contraction) to 5 (normal power) applied to 6 upper and lower limb muscle groups bilaterally (shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and ankle dorsiflexion) [@bb0130]. The ICU-AW was defined as an MRC-SS of less than 48 out of 60 [@bb0085; @bb0095; @bb0135; @bb0140; @bb0145].

2.8. Randomization {#s0085}
------------------

Randomization was managed by the Mental Health and Neuroscience Clinical Trials Unit (London, UK) (see Online Supplement Section E1 for further detail). Treatment allocation was undertaken independently of the research team. Once notified of treatment allocation by the Clinical Trials Unit, participants and relevant treating clinicians were informed. Because of the pilot status of the RCT and the nature of the therapy intervention, blinding of participants and the research team was not possible.

2.9. Intervention {#s0090}
-----------------

Patients randomized to the intervention arm of the RCT completed an EBRP after hospital discharge. Full details of the intervention are detailed in the online supplement (Section E2). In brief, the EBRP is composed of 16 sessions of 40 minutes\' duration, including warm-up and cool-down periods and a combination of cardiovascular, upper and lower limb strength, balance, and functional exercises individually tailored for patients. Sessions occurred twice weekly, in an outpatient physiotherapy gymnasium, supervised by members of the research team. Successful completion of the EBRP was defined a priori as attendance at greater than or 50% of sessions, as per local pulmonary rehabilitation practice [@bb0150], and participants were required to complete acceptability questionnaires at completion. The EBRP was delivered over a 3-month period to allow for other clinical commitments or factors resulting in patient nonattendance. Patients were strongly encouraged to undertake 1 independent exercise session per week using an accompanying exercise manual to guide and record this. The EBRP contained an informal education component where participants were invited to attend sessions covering breathlessness management, benefits of exercise, and nutrition. Furthermore, the research team was available to provide one-to-one advice for participants as required.

2.10. Standard care arm and observational study {#s0095}
-----------------------------------------------

Patients randomized to the standard care arm or enrolled into the observational cohort study received a weekly telephone call from the research team to monitor general progress of recovery. Although in excess of routine standard care, this was mandated by the ethical review board. There was no specific advice on exercise rehabilitation provided during these telephone calls.

2.11. Core outcome measures {#s0100}
---------------------------

Outcome measures for both the RCT and observational study were assessed at baseline (hospital discharge) and at 3 months ([Fig. 1](#f0005){ref-type="fig"}) and included (1) exercise capacity---Incremental Shuttle Walk Test (ISWT) [@bb0155] and Six Minute Walking Test (6MWT) [@bb0160]; and (2) health-related quality of life---Short Form 36 v.2 questionnaire (SF-36, Acute Recall version) [@bb0165] physical (PCS) and mental (MCS) component scores and the Hospital Anxiety and Depression Scale (HADS) [@bb0170]. Feasibility outcomes, including screening, eligibility and recruitment rates, adherence to the EBRP, duration of exercise, information to guide education provision, results across a range of outcome measures, and clinical data associated with the ICU stay were collected and analyzed. Additional outcome measures are detailed in the online supplement (Section E3).

2.12. Statistical analysis {#s0105}
--------------------------

All data are expressed as mean ± SD or median (interquartile range \[IQR\]) as appropriate. Appropriate comparative tests were applied to determine within-group and between-group differences in both the pilot RCT and observational studies. For analyses between the randomized cohort with ICU-AW and the observational cohort without ICU-AW, these were limited to outcomes related to physical performance based on the rationale that these had the potential to be more influenced by degree of global peripheral skeletal muscle strength.

3. Results {#s0015}
==========

3.1. Feasibility of the exercise-based rehabilitation intervention in patients with ICU-AW {#s0110}
------------------------------------------------------------------------------------------

### 3.1.1. Recruitment to a pilot feasibility RCT {#s0115}

Patients were recruited between February 2010 and May 2012 with follow-up completed by August 2012. Participant flow-through is described in the Consolidated Standards of Reporting Trials [@bb0175] diagram ([Fig. 2](#f0010){ref-type="fig"}). A large proportion of all potentially eligible patients were excluded (n = 743), 10 of whom declined consent ([Table 1](#t0005){ref-type="table"}). Further detail on the hospital discharge outcomes of excluded patients and interpretation of eligibility criteria are reported in the online supplement (Section E4). Twenty patients provided informed consent. These data indicate that 37 eligible patients were approached for 1 patient to be successfully recruited, albeit the logistics of screening across 2 study sites may have influenced this ratio. Consent rate in approached patients was 66.7% (20 of 30). Ten patients were randomized into each trial group. Baseline characteristics of the cohort are reported in [Table 2](#t0010){ref-type="table"}. The groups were similar for all characteristics. MRC-SS for the cohort with ICU-AW was 43.0 (39.0-44.8).

### 3.1.2. Adherence to the EBRP {#s0120}

Of the 10 patients randomized to receive the EBRP, 8 successfully completed the intervention with 16.0 (9.3-16.0) sessions attended. Of the 2 patients who failed to complete the program, 1 attended only once due to recurrent chest infections with a subsequent reluctance to continue with the intervention. The second patient attended 7 sessions but was unable to continue participation due to a general deterioration in health related to a separate illness diagnosis (Addison\'s disease). For 2 of the 8 patients who, by definition, successfully completed the intervention, the reasons for not attending all 16 sessions included seasonal chest infections, family circumstances, and separate clinical appointments necessitating hospital attendance.

### 3.1.3. Adverse events {#s0125}

There were no adverse events during any of the EBRP sessions. One patient in the intervention arm was admitted to hospital for investigation of cardiac symptoms occurring outside of the program, which were unrelated to exercise participation. On discharge, this patient was medically approved to resume full participation in the intervention.

### 3.1.4. Patient exercise time per session {#s0130}

Within each session of the EBRP, patients could exercise for 25 minutes (total 40 minutes with warm-up and cool-down time). Patient exercise time per session was 21.9 (20.9-23.4) minutes, which remained consistent with the exclusion of noncompleters (21.9 (21.0-23.2) minutes.

### 3.1.5. Educational sessions {#s0135}

Patients attended an average of 5 education sessions. Individual advice was also provided by the research team where necessary. It was therefore not possible to quantify or analyze this input in a standardized manner.

### 3.1.6. Patient acceptability {#s0185}

Of the 8 patients successfully completing the EBRP, 6 completed a simple acceptability questionnaire requesting their opinion on the experience of participation with regard to the exercise component, and both the formal (classes) and informal (individual advice provided by research team) education sessions ([Table 3](#t0015){ref-type="table"}). All 6 patients reported that, overall, they were "very satisfied" with the program and that it had assisted their recovery after their illness. Furthermore, all patients reported greater understanding and knowledge around exercise participation, and that increasing their fitness levels had assisted in performance of activities of daily living. Only 1 patient reported that attendance at the hospital for the EBRP was "too tiring." Further details on patient acceptability of the EBRP are reported in the online supplement (Section E5).

### 3.1.7. Core outcomes {#s0190}

All patients in the intervention group and 6 patients in the standard care group completed follow-up at 3 months ([Fig. 2](#f0010){ref-type="fig"}). Results of outcome measures are reported in [Table 4](#t0020){ref-type="table"} and in the online supplement (Section E6). There were no between-group differences at baseline, change from baseline or at completion of the trial. Where minimum clinically important difference (MCID) data were available, both the intervention and the standard care group improved beyond these limits. This included 47.5 m for the ISWT [@bb0180] and 54 m for the 6MWT [@bb0185], albeit these data are established for chronic respiratory disease populations. Interestingly, but not unexpected, none of the patients achieved their predicted distance for 6MWT at completion [@bb0190]. Predicted distance for 6MWT for the cohort was 490.1 m (459.8-536.5 m), and percent predicted 6MWT achieved was 66.4% (46.2%-89.1%). By hospital discharge, commencement of the EBRP, the MRC-SS of the randomized cohort was 56.0 (52.0-58.0), increasing to 60.0 (56.0-60.0) at completion, indicating that these patients no longer exhibited ICU-AW, as measured by the MRC-SS threshold of \< 48/60.

3.2. Natural recovery of post critical illness patients without ICU-AW {#s0150}
----------------------------------------------------------------------

### 3.2.1. Recruitment to an observational cohort study {#s0155}

Failure to meet the inclusion criterion of demonstrating an MRC-SS \< 48/60, that is, a diagnosis of ICU-AW, was evident in 132 of the 743 ineligible patients. Of these 132 patients, 21 met all other eligibility criteria and consented to participate in the observational follow-up study of patients without ICU-AW ([Fig. 3](#f0015){ref-type="fig"}). One patient was unable to complete any baseline testing during the hospital stay due to lack of availability for testing and was therefore withdrawn. A further 6 patients did not complete the study. Baseline characteristics for the observational cohort are reported in [Table 2](#t0010){ref-type="table"}. MRC-SS for the group at enrolment at ICU discharge was 56.5 (53.3-59.8).

### 3.2.2. Core outcomes {#s0160}

Results in outcome measures for the observational cohort are presented in [Table 5](#t0025){ref-type="table"} and the online supplement (Section E7). Improvements were observed in both ISWT and 6MWT that exceeded the reported MCID for each test [@bb0180; @bb0185]. Predicted 6MWT distance at completion for the cohort was 552.0 m (480.2-621.6 m), and percent predicted distance achieved was 74.4% (58.0%-93.5%). Improvements were also observed in health-related quality of life between baseline and completion (SF-36 PCS, 34.0 \[28.2-41.4\] to 42.7 \[35.7-48.5\], *P* = .01; SF-36 MCS, 44.4 \[34.9-52.6\] to 51.4 \[43.1-57.2\], *P* = .03). MRC-SS for the observational cohort at hospital discharge was 60.0 (57.0-60.0), and at completion, 60.0 (60.0-60.0).

3.3. Recovery of patients with ICU-AW and those without ICU-AW {#s0165}
--------------------------------------------------------------

Comparison of baseline characteristics between the randomized cohort with ICU-AW and the observational cohort without ICU-AW is presented in [Table 2](#t0010){ref-type="table"}. The male-to-female ratio was greater in the observational cohort (*P* = .005). Patients with ICU-AW were sicker at ICU admission, with significantly higher illness severity (Acute Physiology and Chronic Health Evaluation II) scores than those without ICU-AW (23.5 \[20.3-29.5\] vs 17.0 \[12.5-19.5\], *P* \< .0001). Furthermore, these patients experienced a longer post ICU in-hospital ward stay (23.5 \[10.3-43.0\] days vs 13.0 \[6.5-19.5\] days, *P* = .03), but only a trend to extended total hospital stay (46.0 (25.0-61.8\] days vs 30.0 \[19.5-47.5\], *P* = 0.2).

### 3.3.1. Core outcomes {#s0170}

Comparison of the outcomes between groups is summarized in [Table 6](#t0030){ref-type="table"}. There were no consistent between-group differences at baseline and completion of the study. Furthermore, there was no difference in baseline to completion change. However, at a group level, patients without ICU-AW demonstrated greater ISWT distances at completion (365.0 m \[250.0-477.5 m\] vs 200.0 m \[120.0-330.0 m\], *P* = 0.03), with greater change (265.0 m (207.5-300.0 m\] vs 120.0 m \[10.0-230.0 m\], *P* = .047). In addition, there was a higher SF-36 PCS (34.0 \[28.2-41.4\] vs 29.4 \[19.7-32.9\], *P* = .03) and SF-36 physical function domain (40.0 \[15.0-66.3\] vs 12.5 \[5.0-27.5\], *P* = .005) in those patients without ICU-AW at baseline, although this between-group difference was not present at completion. Patients without ICU-AW had enhanced physical performance as measured by the Timed Up And Go test at baseline (14.8 \[13.1-18.5\] vs 21.0 \[16.0-36.0\], *P* = .04), but there were no differences between the groups observed in the Barthel and Sit to Stand 5 tests.

### 3.3.2. Relationship between ICU-AW and physical function {#s0175}

Extended analyses of the relationship between ICU-AW and physical function performance at study milestones is shown in the on line supplement (Sections E8).

### 3.3.3. Sample size {#s0180}

The calculated sample sizes for a future trial are reported in the online supplement (Section E9).

4. Discussion {#s0020}
=============

This pilot RCT investigating exercise-based rehabilitation delivered after hospital discharge in survivors of critical illness with ICU-AW demonstrated that the intervention was feasible as evidenced by the high completion rate, an absence of adverse events, and strong patient-reported acceptability. However, the change in diagnostic status of ICU-AW between patient enrolment and commencement of the intervention indicates that using manual muscle testing for determining presence of weakness lacked robustness as an eligibility criterion for participation. Furthermore, the observation of the natural recovery of patients without ICU-AW revealed inconsistent differences in outcomes between this cohort and those patients with weakness, indicating that stratification for exercise rehabilitation requirements using this approach lacked satisfactory discrimination, which was demonstrated by the ceiling effect of the MRC-SS test.

4.1. Clinical significance of the findings {#s0195}
------------------------------------------

This study was not powered to detect differences between groups across any of the clinical, mechanistic, and patient-centered outcomes, and therefore cannot suggest effectiveness of the intervention limiting comparison with findings from previously reported trials [@bb0045; @bb0075; @bb0080]. Despite this, specification of a diagnosis of ICU-AW, measured by the MRC-SS at ICU discharge as a specific eligibility criterion was a novel aspect of this pilot trial, based on the extensive data reporting a causal association between an MRC-SS less than 48 and poor clinical outcome [@bb0085; @bb0090; @bb0095; @bb0100; @bb0105; @bb0110; @bb0115] and the rationale for greater rehabilitation requirements. Although since this trial was first designed, use of the MRC-SS threshold for diagnosing ICU-AW has been shown to lack both sensitivity and specificity to predict clinical outcome [@bb0195], in this study, the diagnosis ICU-AW failed to define the most appropriate target group for an exercise-based rehabilitation intervention. Indeed, at ICU discharge, patients with ICU-AW and those without had similar baseline characteristics. By hospital discharge, when the intervention commenced, those patients with ICU-AW at ICU discharge had improved clinically, demonstrating an MRC-SS greater than 48, such that they could be recategorized as without ICU-AW. This ceiling effect limits the clinical usefulness of MRC-SS testing.

Presence of ICU-AW at ICU discharge did, however, alter the ward-based therapy provision for these patients and influence their trajectory of recovery during this period. These patients were the sickest patients at ICU admission, and based on our previous data were those likely to have undergone greater muscle wasting during the first week of critical illness [@bb0005]. It is postulated that the ward stay of such patients was protracted while they received more intense rehabilitation interventions than those without ICU-AW to achieve a level of function sufficient for hospital discharge, at which point the MRC-SS could not distinguish between the groups. Unfortunately, these data were not captured in this study, nor indeed were data regarding the dose of rehabilitation or other ICU exposures received by patients during their preceding ICU stay. Future trials must carefully characterize the pretrial period rehabilitation and other factors that could influence outcome and recovery in patients, in detail [@bb0200].

Both trial and observational study cohorts demonstrated improvements in exercise capacity and subjective physical function scores beyond currently available MCID data, albeit specific values for the post--critical illness population have yet to be established, and we acknowledge these were pilot patient numbers. However, natural recovery exceeding the current MCID has clinical relevance, and it is important to note as any future rehabilitation intervention would need to demonstrate effectiveness beyond this level. In addition, the rate of recovery trajectory also requires consideration to deliver the intervention at the optimal time point during recovery. MCID data for outcomes should be applicable to the relative stage of recovery, as this will ultimately influence the effect of the intervention. Satisfactory recovery with standard management in the early recovery period could result in resource allocation to the later stages of the patient pathway when there is a greater clinical need.

4.2. Critique of the method {#s0200}
---------------------------

Process evaluation can distinguish failure of an intervention to cause an effect from failure of effective delivery of the intervention [@bb0205; @bb0210] and is integral to the development, evaluation, and reporting of complex interventional trials [@bb0215], such as exercise rehabilitation in the post--critical illness population. The pilot nature of this trial precluded detecting effectiveness of the intervention, and so, we focused on retrospective evaluation of methodological considerations around trial design, an important feature and outcome associated with pilot trials [@bb0220]. Undertaking this process is a particular strength of this feasibility study, informing our understanding of aspects that would require consideration in a future, larger scale study. We adopted the population, intervention, control, and outcome construct, so called "PICO" principle, to assess the present trial and provide a framework for discussion [@bb0225; @bb0230].

### 4.2.1. Population {#s0205}

Heterogeneity of post--critical illness patients challenges the delivery and evaluation of rehabilitation throughout the recovery pathway, with individual patterns of response to interventions evident. Trial eligibility criteria aim to enrol more homogenous cohorts, and those adopted in this study were consistent with previous trials. This resulted, however, in an extremely low ratio of included to excluded patients and indeed has attributed to failure to reach a priori sample sizes in prior larger scale studies [@bb0045; @bb0080]. Further definition of the patients most likely to benefit from post--hospital discharge rehabilitation is required [@bb0235] to maximize recruitment. Experience from this study challenges the usefulness of measuring peripheral skeletal muscle strength using manual muscle testing. Measures of physical functional performance that reflect residual impairment are more likely to be useful, but require validation. The severity of the acute critical illness determines the degree of skeletal muscle wasting, and the presence of preexisting chronic disease states determines the trajectory of the recovery pathway, and both need to be considered in any future trials [@bb0240]. Assessment for eligibility, randomization, and commencement of the intervention should be synchronous to ensure that natural recovery is accommodated into the trial design in both the control and intervention group, and the intervention is being tested effectively. Furthermore, in light of greater recognition of the cognitive affects associated with critical illness, in any future trial of exercise-based rehabilitation, the cognitive ability of patients will need to be assessed and delirium excluded along with the usual assesment for mental capacity status\'.

### 4.2.2. Intervention {#s0210}

Post--intensive care syndrome encompasses a range of physical, psychological, cognitive, and physical impairments for survivors of critical illness [@bb0010]. The current trial focused on an exercise-based intervention primarily targeted toward physical recovery. The failure to address other morbidities of critical illness [@bb0235] may have contributed to the outcome, although this would only be confirmed by a fully powered trial. In the future, multidisciplinary, multimodal rehabilitation programs may elicit greater response through the synergistic effect of optimizing 1 element on another, for example, physical performance and mental health.

The optimum exercise prescription to enhance physical recovery in post--critical illness patients has yet to be determined. This pilot study conformed with recommendations for nonpharmacological trials by closely detailing the intervention [@bb0245]. Nonetheless, the chosen content, format, and route of delivery may not have been preferable for all participants. That said, high completion rates were evident, but we acknowledge that this may have, in part, been influenced by the provision of transport to and from the hospital, which may not always be available in routine clinical practice. Clinical factors accounted for the majority of nonattendances, which may also affect adherence to rehabilitation delivered via other formats.

Because this is a pilot feasibility trial, future studies are required to test if the current exercise prescription would be sufficient to cause physiological improvement in a larger sample, even with the employment of target intensity levels and measures for monitoring this. We delivered the intervention in tandem with existing pulmonary rehabilitation programs for patients with chronic respiratory disease for pragmatic and logistical reasons, and we acknowledge the influence of this in the design of our intervention. Close attention is required to patient education in self-monitoring of exercise and to individual exercise prescription and progression. Cardiopulmonary exercise testing could have a role in determining optimum exercise intensity and guiding exercise delivery, albeit with pragmatic limitations for its frequent widespread clinical availability and implementation.

### 4.2.3. Standard care (control) group {#s0215}

Accurate description of the standard care or control arm in a complex intervention trial is important for enhanced interpretation and generalizability of the results [@bb0250; @bb0255]. Methods such as benchmarking or point prevalence studies to detail and evaluate existing practice have recently reported to the timing and intensity of exercise rehabilitation in the ICU [@bb0260; @bb0265; @bb0270]. Standardized reporting of usual practice can improve safety monitoring, facilitate and accelerate the translation of research findings into local clinical practice, and enhance the understanding of differences between groups with regard to intensity of interventions received [@bb0275; @bb0280].

In this study, the standard care arm received a weekly telephone call from the research team, mandated by the ethical review board. While no specific advice regarding exercise rehabilitation was provided during these phone calls, this represents additional input than these patients would normally receive. Furthermore, standard care patients could also be discharged from hospital in receipt of generic rehabilitation services such as intermediate care or community therapy at the discretion of the clinical team. Lack of formal evaluation of additional services received by these patients represents a methodological weakness of the current protocol. These interventions could have contributed to expediting recovery, albeit given the small sample size this would not have been possible to determine in the current trial.

### 4.2.4. Outcome measures {#s0220}

Various outcome measures are used in survivors of critical illness to assess physical functional and performance, although the psychometric properties of these tests have yet to be ascertained [@bb0285]. Indeed, appropriate outcome measures for evaluation of rehabilitation interventions remain undetermined [@bb0235]. Outcome measures must be responsive to change with close consideration for the relative floor and ceiling effects. For complex intervention trials, a core outcome set may be required to best reflect the response to an intervention, which would be applicable to the specific stage of recovery [@bb0045]. In contrast, implementing such a battery of assessment measures may be difficult to achieve due to excessive testing burden, and a clear balance between testing burden and robust outcome data must be found. In the current trial, we observed "testing burden and measurement fatigue" potentially resulting in poor test performance and missing data, which in a larger trial would result in increased trial attrition. A consensus-driven core set of outcomes to evaluate effectiveness of rehabilitation interventions would guide future trial protocols [@bb0290; @bb0295]. As this outcome set, there would also be a requirement to develop a specific bespoke post--critical illness tool to monitor recovery based on the qualitative assessment of patient experiences.

5. Conclusion {#s0045}
=============

In this pilot trial, an EBRP after hospital discharge for survivors of critical illness with ICU-AW was feasible in delivery and patient acceptance, albeit the study was underpowered to demonstrate intervention effectiveness. Diagnosis of ICU-AW, based on results of manual muscle testing, conferred limited clinical use as an eligibility criterion for participation in such a rehabilitation program, and in identifying patients most likely to benefit from rehabilitation after hospital discharge. Process evaluation identified methodological factors for consideration in the design, conduct, and implementation of a future trial, notably focused on eligibility criteria, intensity, and timing of intervention delivery and appropriate outcomes for evaluating effectiveness.
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![Schematic outline of pilot RCT and observational study pathway.\
\*Note that patients in the observational study did not undergo randomization but were managed in the same way as the control group of the RCT.](gr1){#f0005}

![Consolidated standards of reporting trials diagram detailing patient flow-through within the RCT.](gr2){#f0010}

![Flow diagram detailing participant flow through observational study of clinically strong patients.](gr3){#f0015}

###### 

Factors accounting for ineligibility into the RCT

  Factor                                    Frequency of occurrence (%)   Classification
  ----------------------------------------- ----------------------------- -----------------------------
  Ventilation ≥ 48 h                        294 (39.6)                    Inclusion criterion not met
  Extracontractual tertiary referral        185 (24.9)                    Exclusion criterion met
  MRC-SS \< 48/60                           132 (17.8)                    Inclusion criterion not met
  Existing rehabilitation pathway           131 (17.6)                    Exclusion criterion met
  Sufficient mobility                       97 (13.1)                     Inclusion criterion not met
  ICU admission ≥ 48 h                      95 (12.8)                     Inclusion criterion not met
  Expected survival to hospital discharge   93 (12.5)                     Inclusion criterion not met
  Palliative/terminal prognosis             89 (12.0)                     Exclusion criterion met
  Complex medical comorbidity               82 (11.0)                     Exclusion criterion met
  Disabling condition precluding exercise   80 (10.8)                     Exclusion criterion met
  Unstable cardiac diagnoses                75 (10.1)                     Exclusion criterion met
  Neurological diagnoses                    64 (8.6)                      Exclusion criterion met
  Impaired GCS                              42 (5.7)                      Exclusion criterion met
  Psychiatric diagnoses                     42 (5.7)                      Exclusion criterion met
  Ongoing renal haemodialysis               32 (4.3)                      Exclusion criterion met
  Acute limb amputation                     13 (1.7)                      Exclusion criterion met
  Acute peripheral vascular disease         5 (0.7)                       Exclusion criterion met
  Age \> 18 y                               4 (0.5)                       Inclusion criterion not met

Data are presented as number (percentage), and report frequency of reported occurrence of each criterion; therefore. total percentages exceed 100% (n = 733). Multiple factors could apply per patient. GCS indicates Glasgow Coma Scale.

###### 

Baseline characteristics for standard care and intervention arms of the pilot RCT and the observational cohort study

  Characteristic                                         Standard care group (n = 10)   Intervention group (n = 10)   Pooled randomized cohort (ICU-AW) (n = 20)   Observational cohort (MRC-SS ≥ 48/60) (n = 21)   *P*
  ------------------------------------------------------ ------------------------------ ----------------------------- -------------------------------------------- ------------------------------------------------ ----------
  Age (y)                                                68.5 (64.3-78.0)               63.0 (46.8-71.8)              66.5 (54.5-73.3)                             63.0 (49.5-70.0)                                 .3
  Sex (male/female)                                      3:7                            3:7                           6:14                                         16:5                                             .005^\~^
  ICU diagnosis[a](#tf0005){ref-type="table-fn"} (%)                                                                                                                                                                
   Medical                                               6 (60)                         7 (70)                        13 (65)                                      15 (71.4)                                        .7^\~^
   Surgical                                              4 (40)                         3 (30)                        7 (35)                                       6 (28.6)                                         n/a
  Chronic disease[a](#tf0005){ref-type="table-fn"} (%)                                                                                                                                                              
   Respiratory                                           4 (40)                         7 (70)                        11 (55)                                      7 (33.3)                                         .07^\~^
   Cardiac                                               5 (50)                         4 (40)                        9 (45)                                       7 (33.3)                                         .2^\~^
   Other[b](#tf0010){ref-type="table-fn"}                5 (50)                         3 (30)                        8 (40)                                       10 (47.6)                                        .8^\~^
  APACHE II                                              23.5 (21.0-30.3)               24.5 (18.8-29.5)              23.5 (20.3-29.5)                             17.0 (12.5-19.5)                                 \< .0001
  SOFA (ICU admission)                                   12.0 (7.5-14.3)                9.5 (8.0-12.5)                11.0 (8.0-13.5)                              10.0 (7.5-12.0)                                  .4
  Duration MOF (days)                                    10.5 (5.8-13.3)                9.5 (6.8-15.3)                10.0 (6.0-12.8)                              9.0 (3.5-14.5)                                   .6
  MV (d)                                                 11.2 (6.0-15.2)                9.3 (6.0-13.9)                10.2 (6.8-14.0)                              9.0 (4.3-20.4)                                   1.0
  CPAP (d)                                               2.0 (0.3-4.6)                  1.3 (0.04-6.9)                1.3 (0.2-5.0)                                1.5 (0.4-2.6)                                    .6
  Tracheostomy (%)                                       3 (30)                         5 (50)                        8 (40)                                       8 (38.1)                                         --
  ICU LOS (d)                                            13.0 (9.8-20.5)                14.5 (7.0-17.8)               13.5 (8.5-19.3)                              10.0 (6.5-27.0)                                  .9
  CC LOS (d)                                             18.0 (13.8-36.5)               17.5 (9.0-27.3)               18.0 (11.5-31.8)                             13.0 (10.0-37.0)                                 .8
  Ward LOS (d)                                           27.5 (10.0-46.3)               20.0 (10.0-43.0)              23.5 (10.3-43.0)                             13.0 (6.5-19.5)                                  .03
  Hospital LOS (d)                                       47.5 (26.5-68.5)               39.0 (22.3-66.5)              46.0 (25.0-61.8)                             30.0 (19.5-47.5)                                 .2

Data are presented as median (IQR) or number (percentage). Standard care and intervention groups were similar for all characteristics (all *P* = ns therefore not reported). *P* values derived from Mann-Whitney test or Fisher exact test^\~^ and reflect difference between pooled data from groups within the randomized cohort with ICU-AW and the clinically strong observational cohort. Note: 1 *P* value applicable for contingency analysis of proportion of medical and surgical patients across both groups. APACHE indicates acute physiology and chronic health evaluation; SOFA, Sequential Organ Failure Assessment; MOF, multiorgan failure; CPAP, continuous positive airway pressure; LOS, length of stay; CC, critical care.

ICU diagnosis and chronic disease indicates frequency of occurrence. Patients could present with more than 1 comorbidity.

Other chronic comorbidities included diabetes mellitus, osteoarthritis/gout, stable chronic renal disease.

###### 

Items and responses from patient acceptability questionnaire in the pilot RCT

  Item                                                                                 Responses
  ------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------
  1\. Attending the exercise program helped recovery from my illness                   66.7% strongly agree, 33.3% agree
  2\. I have a clear picture of how exercise will help my fitness                      66.7% strongly agree, 33.3% agree
  3\. I have a clear picture of how fitness will help in daily activities of my life   66.7% strongly agree, 33.3% agree
  4\. I feel confident doing exercise                                                  66.7% strongly agree, 33.3% agree
  5\. I worry that exercise may be harmful to me                                       33.3% strongly disagree, 66.7% disagree
  6\. I felt very stressed doing the exercise                                          33.3% strongly disagree, 66.7% disagree
  7\. I found the visits to the hospital too tiring                                    50% strongly disagree, 33.3% disagree, 16.7% agree
  8\. Exercise has not helped me                                                       66.7% strongly disagree, 33.3% disagree
  9\. The way the information was presented                                            16.7% very satisfied, 66.7% satisfied, 16.7% unable to comment
  10\. The information given                                                           16.7% very satisfied, 66.7% satisfied, 16.7% unable to comment
  11\. The opportunities you had to discuss any concerns                               16.7% very satisfied, 66.7% satisfied, 16.7% unable to comment
  12\. The way the staff answered your questions                                       33.3% very satisfied, 50% satisfied, 16.7% unable to comment
  13\. The range of education topics covered                                           16.7% very satisfied, 50% satisfied, 16.7% neither satisfied or dissatisfied, 16.7% unable to comment

Data from 6 patients successfully completing the EBRP. Items 1 to 8 refer to exercise component of program. Items 9 to 13 refer to both formal and informal education sessions. Where response indicates "Unable to comment," this patient did not attend any education sessions.

###### 

Results of outcome measures assessed in the pilot RCT

  Outcome measure         Standard care (n = 6)    Intervention (n = 10)                                                                                
  ----------------------- ------------------------ ------------------------ ------------------------- ------------------------ ------------------------ ------------------------
  ISWT (m)                20.0 (10.0 to 60.0)      190.0 (70.0 to 355.0)    170.0 (40.0 to 315.0)     55.0 (7.8 to 120.0)      200.0 (132.5 to 340.0)   115.0 (− 2.5 to 237.5)
  6MWT (m)                150.0 (100.5 to 207.0)   335.0 (177.5 to 455.0)   185.0 (40.0 to 285.0)     180.0 (125.0 to 221.5)   328.5 (230.0 to 393.8)   140.0 (35.8 to 210.3)
  SF-36 v2 PCS (/100)     20.6 (19.4 to 33.3)      42.3 (27.9 to 47.6)      11.0 (4.3 to 28.3)        29.8 (24.1 to 33.2)      33.2 (23.8 to 45.4)      1.8 (− 6.8 to 15.9)
  SF-36 v2 MCS (/100)     50.9 (35.6 to 57.8)      45.6 (34.3 to 54.7)      − 11.4 (− 19.0 to 19.1)   31.6 (28.6 to 49.1)      53.4 (39.5 to 58.8)      14.3 (− 3.2 to 26.7)
  HADS total (/42)        14.0 (9.0 to 20.0)       6.5 (5.5 to 10.3)        − 4.5 (− 13.3 to − 2.5)   13.0(7.0 to 19.0)        9.0 (3.5 to 10.3)        − 6 (− 9.3 to − 2.8)
  HADS anxiety (/21)      6.0 (1.5 to 11.5)        4.0 (0.8 to 6.0)         0.0 (− 7.0 to 0.0)        7.0 (4.5 to 9.3)         4.0 (1.8 to 5.5)         − 3.5 (− 5.0 to − 1.3)
  HADS depression (/21)   8.5 (7.3 to 10.0)        2.5 (2.0 to 8.0)         − 4.5 (− 6.3 to − 1.8)    5.5 (2.8 to 11.0)        4.5 (1.0 to 7.3)         − 1.5 (− 3.3 to 2.0)

Data are presented as median (IQR).

###### 

Results of outcome measures assessed in the observational cohort study

  Outcome measure       Baseline                Completion               Change                   *P*
  --------------------- ----------------------- ------------------------ ------------------------ -------
  ISWT (m)              80.0 (30.0 to 212.5)    365.0 (250.0 to 477.5)   265.0 (207.5 to 300.0)   .0002
  6MWT (m)              167.0 (60.0 to 293.5)   433.5 (318.3 to 481.0)   157.5 (131.3 to 321.3)   .0002
  SF-36 v2 PCS (/100)   34.0 (28.2 to 41.4)     42.7 (35.7 to 48.5)      6.4 (1.7 to 13.1)        .01
  SF-36 v2 MCS (/100)   44.4 (34.9 to 52.6)     51.4 (43.1 to 57.2)      4.7 (− 1.8 to 11.4)      .03
  HADS                                                                                            
   Total (/42)          10.0 (6.8 to 14.0)      9.0 (6.5 to 13.0)        0.5 (− 3.3 to 4.5)       .8
   Anxiety (/21)        5.0 (3.0 to 7.5)        4.0 (2.8 to 8.3)         0.0 (− 2.0 to 3.3)       .7
   Depression (/21)     5.5 (2.8 to 7.3)        5.5 (1.8 to 7.5)         1.0 (− 2.5 to 3.3)       .8

Data are presented as median (IQR) (n = 14). *P* values derived from Wilcoxon signed rank test and reflect change from baseline to completion.

###### 

Comparison of outcome measures between patients with ICU-AW and clinically strong patients

  Characteristic     Randomized cohort (ICU-AW) (n = 16)   Observational cohort (MRC-SS ≥ 48/60) (n = 14)   *P*
  ------------------ ------------------------------------- ------------------------------------------------ -------
  ISWT (m)                                                                                                  
   Baseline          40 (10.0 to 80.0)                     80.0 (30.0 to 212.5)                             0.1
   Completion        200.0 (120.0 to 330.0)                365.0 (250.0 to 477.5)                           0.03
   Change            120.0 (10.0 to 230.0)                 265.0 (207.5 to 300.0)                           0.047
  6MWT (m)                                                                                                  
   Baseline          160.0 (110.5 to 221.0)                167.0 (60.0 to 293.5)                            0.8
   Completion        330.0 (240.0 to 422.5)                433.5 (318.3 to 481.0)                           0.1
   Change            160.0 (36.5 to 208.5)                 157.5 (131.3 to 321.3)                           0.5
  SF-36 PCS (/100)                                                                                          
   Baseline          29.4 (19.7 to 32.9)                   34.0 (28.2 to 41.4)                              0.03
   Completion        34.6 (46.5 to 55.1)                   42.7 (35.7 to 48.5)                              0.2
   Change            6.3 (− 3.2 to 16.2)                   6.4 (1.7 to 13.1)                                0.9
  SF-36 PF (/100)                                                                                           
   Baseline          12.5 (5.0 to 27.5)                    40.0 (15.0 to 66.3)                              0.005
   Completion        40.0 (20.0 to 73.8)                   70.0 (41.8 to 80.0)                              0.1
   Change            20.0 (0.0 to 60.0)                    23.5 (3.8 to 31.3)                               0.8
  Barthel (/100)                                                                                            
   Baseline          87.5 (75.0 to 95.0)                   97.5 (85.0 to 100.0)                             0.08
   Completion        100.0 (86.3 to 100.0)                 100.0 (98.8 to 100.0)                            0.5
   Change            10.0 (1.3 to 23.8)                    0.0 (0.0 to 15.0)                                0.2
  TUAG (s)                                                                                                  
   Baseline          21.0 (16.0 to 36.0)                   14.8 (13.1 to 18.5)                              0.04
   Completion        10.0 (8.0 to 19.0)                    8.0 (6.8 to 10.0)                                0.06
   Change            − 7.0 (−24.0 to −2.0)                 − 6.0 (− 9.3 to − 3.8)                           0.6
  STS-5 (s)                                                                                                 
   Baseline          22.5 (16.8 to 29.5)                   19.0 (10.8 to 26.0)                              0.3
   Completion        16.0 (11.5 to 20.0)                   11.4 (8.9 to 17.5)                               0.2
   Change            − 3.8 (− 15.0 to 1.9)                 − 3.5 (− 11.0 to − 0.5)                          0.98

Data are presented as median (IQR). *P* values derived from Mann-Whitney test analysis. n = 14 for TUAG and STS-5 for the randomized cohort. SF-36 v2 PF indicates Short Form-36 v2 Physical Function domain; TUAG, Timed Up and Go; STS-5, Sit to Stand 5 times.
